



IncobotulinumtoxinA (Xeomin) injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders

Last updated: 5 February 2026

- **What?** From **1 March 2026**, MBS item 18355 will be introduced to allow for the injection of IncobotulinumtoxinA (Xeomin) for patients with chronic sialorrhea due to neurological or neurodevelopmental disorders.
- **Who?** These changes are relevant to patients and providers, including neurologists, rehabilitation specialists, ear, nose and throat surgeons, and plastic surgeons for all populations. More specifically, these changes are relevant for geriatricians treating the adult population and paediatricians treating the paediatric population.
- **What does this mean for patients and providers?** Patients and providers will have access to a new Medicare Benefit Schedule (MBS) service to treat chronic sialorrhea due to neurological or neurodevelopmental disorders.

What are the changes?

Effective 1 March 2026, there will be a new item for Botulinum toxin injections. The new structure introduces:

- 1 new item, MBS item 18355, for the injection of IncobotulinumtoxinA (Xeomin) for the treatment of chronic sialorrhea in patients due to neurological or neurodevelopmental disorders.

For private health insurance purposes, MBS item 18355 will be listed under the following clinical category and procedure type:

- Private Health Insurance Classification:
- Clinical category: Ear, nose and throat
- Procedure type: Type C

Why are the changes being made?

The listing of this service was recommended by the Medical Services Advisory Committee (MSAC) in April 2025. Further details about MSAC applications can be found under [MSAC Applications](#) on the MSAC website ([Medical Services Advisory Committee](#)).

What does this mean for providers?

Providers will gain access to a new MBS service to treat chronic sialorrhea in patients due to neurological or neurodevelopmental disorders.

Providers should familiarise themselves with [Pharmaceutical Benefit Scheme \(PBS\) requirements](#) when providing this service to patients.

How will these changes affect patients?

The changes will provide greater access to a new treatment for patients, leading to improved health outcomes. Patients will receive Medicare benefits for the clinically appropriate treatment of chronic sialorrhea due to neurological or neurodevelopmental conditions.

Who was consulted on the changes?

As a part of the MSAC evaluation process, feedback on the proposed service was extended to members of the public and targeted peak medical bodies and groups. The Rehabilitation Medicine Society of Australia and New Zealand and the Movement Disorder Society of Australia and New Zealand positively endorsed the creation on this new MBS item.

How will the changes be monitored and reviewed?

Providers are responsible for ensuring Medicare services claimed using their provider number meet all legislative requirements. All Medicare claiming is subject to compliance checks and providers may be required to submit evidence about the services they bill. More information about the Department of Health, Disability and Ageing's (the department's) compliance program can be found on its website at [Medicare compliance](#).

Where can I find more information?

The full item descriptor(s) and information on other changes to the MBS can be found on the [MBS Online website](#). You can also subscribe to future MBS updates by visiting '[Subscribe to the MBS](#)' on the MBS Online website.

Providers seeking advice on interpretation of MBS items, explanatory notes and associated legislation can use the department's email advice service by emailing askMBS@health.gov.au.

Private health insurance information on the product tier arrangements is available at www.privatehealth.gov.au. Detailed information on the MBS item listing within clinical categories is available on the [department's website](#). Private health insurance minimum accommodation benefits information, including MBS item accommodation classification, is available in the latest version of the *Private Health Insurance (Benefit Requirements) Rules 2011* found on the [Federal Register of Legislation](#). If you have a query in relation to private health insurance, you should email PHI@health.gov.au.

Subscribe to '[News for Health Professionals](#)' on the Services Australia website to receive regular news highlights.

If you are seeking advice in relation to Medicare billing, claiming, payments, or obtaining a provider number, please go to the Health Professionals page on the Services Australia website or contact Services Australia on the Provider Enquiry Line – 13 21 50.

The data file for software vendors when available can be accessed via the [Downloads](#) page.

New item descriptor (to take effect 1 March 2026)

Category 3- Therapeutic procedures

Group T11 – Botulism toxin injections

MBS item 18355

IncobotulinumtoxinA (Xeomin), injection of, for the treatment of chronic sialorrhea in a patient who is at least 2 years of age, if the condition is due to a neurological or neurodevelopmental disorder, including all such injections on any one day (Anaes.)

Fee: \$145.65 Benefit: 75% = \$109.25 85% = \$123.85

Private Health Insurance Classification:

- Clinical category: Ear, nose and throat
- Procedure type: Type C

Please note that the information provided is a general guide only. It is ultimately the responsibility of treating practitioners to use their professional judgment to determine the most clinically appropriate services to provide, and then to ensure that any services billed to Medicare fully meet the eligibility requirements outlined in the legislation.

This factsheet is current as of the Last updated date shown above and does not account for MBS changes since that date.